Application of resveratrol in diabetes: Rationale, strategies and challenges

Current Molecular Medicine

Volumn 15, Issue 4, 2015, Pages 312-330

  Bagul, P K ^a   Banerjee, S K ^a  

^a Translational Health Science and Technology Institute (THSTI)   (India)

Author keywords

Clinical studies; Diabetes; Insulin resistance; Molecular mechanism; Resveratrol; Sirtuins

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; GLUCOSE TRANSPORTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; PROTEIN NOXA; PUMA PROTEIN; RESVERATROL; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARDIOTONIC AGENT; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; SLC2A4 PROTEIN, HUMAN; STILBENE DERIVATIVE;

AGING; ANTIDIABETIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERPOLARIZATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NANOTECHNOLOGY; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; MOUSE; OXIDATIVE STRESS; PHYSIOLOGY; RAT;

ANIMALIA;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARBOHYDRATE METABOLISM; CARDIOTONIC AGENTS; DIABETES MELLITUS; ENZYME ACTIVATION; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; OXIDATIVE STRESS; RATS; SIRTUIN 1; STILBENES;

EID: 84930983044     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150505155702     Document Type: Article

References (167)

1. [1] Thevenod F. Pathophysiology of diabetes mellitus type 2: roles of obesity, insulin resistance and cell dysfunction. Diabetes Cancer 2008; 19: 1-18.
2. [2] Shomali M. Diabetes treatment in 2025: can scientific advances keep pace with prevalence? Ther Adv Endocrinol Metab 2012; 3: 163-73.
3. [3] Malecki MT. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 68(Suppl 1): S10-21.
4. [4] Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-97.
5. [5] Bloomgarden ZT. Exploring treatment strategies for type 2 diabetes. Diabetes Care 2007; 30: 2737-45.
6. [6] Sena CM, Bento CF, Pereira P, Seica R. Diabetes mellitus: new challenges and innovative therapies. EPMA J 2010; 1: 138-63.
7. [7] Minocha M, Gobburu J. Drug Development and potential regulatory paths for insulin biosimilars. J Diabetes Sci Technol 2014; 8: 14-9.
8. [8] Leiherer A, Mundlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 2013; 58: 3-20.
9. [9] Stewart JR, Artime MC, O'Brian CA. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 2003; 133: 2440S-3S.
10. [10] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
11. [11] Bland J. Resveratrol opportunism: what is the science behind the claims? Integr Med 2009; 7: 50-51.
12. [12] Sadruddin S, Arora R. Resveratrol: biologic and therapeutic implications. J Cardiometab Syndr 2009; 4: 102-6.
13. [13] Hanhineva K, Torronen R, Bondia-Pons I, et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 2010; 11: 1365-402.
14. [14] Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY) 2012; 4: 146-58.
15. [15] Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 1998; 138: 619-20.
16. [16] Sun AY, Simonyi A, Sun GY. The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic Biol Med 2002; 32: 314-8.
17. [17] Bagul PK, Banerjee SK. Insulin resistance, oxidative stress and cardiovascular complications: role of sirtuins. Curr Pharm Des 2013; 19: 5663-77.
18. [18] Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 2010; 131: 261-9.
19. [19] Halls C, Yu O. Potential for metabolic engineering of resveratrol biosynthesis. Trends Biotechnol 2008; 26: 77-81.
20. [20] Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
21. [21] Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta 2015; 1852: 1114-23.
22. [22] Pirola L, Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 2008; 60: 323-32.
23. [23] Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-9.
24. [24] Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006; 76: 69-75.
25. [25] Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocininduced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290: E1339-46.
26. [26] Hambrock A, de Oliveira Franz CB, Hiller S, et al. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem 2007; 282: 3347-56.
27. [27] Chi TC, Chen WP, Chi TL, et al. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 2007; 80: 1713-20.
28. [28] Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol 2009; 26: 17-22.
29. [29] Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009; 58: 344-51.
30. [30] Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007; 6: 307-19.
31. [31] Penumathsa SV, Thirunavukkarasu M, Zhan L, et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 2008; 12: 2350-61.
32. [32] Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 2009; 179: 356-62.
33. [33] Schmatz R, Schetinger MR, Spanevello RM, et al. Effects of resveratrol on nucleotide degrading enzymes in streptozotocin-induced diabetic rats. Life Sci 2009; 84: 345-50.
34. [34] Schmatz R, Mazzanti CM, Spanevello R, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 2009; 610: 42-8.
35. [35] Yu ZW, Li D, Ling WH, Jin TR. Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: A novel opportunity for diabetes treatment? World J Diabetes 2012; 3: 19-28.
36. [36] Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 299: H18-24.
37. [37] Zhang H, Morgan B, Potter BJ, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010; 299: H985-94.
38. [38] Tang PC, Ng YF, Ho S, Gyda M, Chan SW. Resveratrol and cardiovascular health--promising therapeutic or hopeless illusion? Pharmacol Res 2014; 90: 88-115.
39. [39] Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 2013; 168: 934-45.
40. [40] Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 2011; 1215: 1-8.
41. [41] Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-95.
42. [42] Raval AP, Lin HW, Dave KR, et al. Resveratrol and ischemic preconditioning in the brain. Curr Med Chem 2008; 15: 1545-51.
43. [43] Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta 2015; 1852: 1195-1201.
44. [44] Pallas M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A. Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov 2008; 3: 61-9.
45. [45] Hector KL, Lagisz M, Nakagawa S. The effect of resveratrol on longevity across species: a meta-analysis. Biol Lett 2012; 8: 790-3.
46. [46] Sadowska-Bartosz I, Bartosz G. Effect of antioxidants supplementation on aging and longevity. Biomed Res Int 2014; 2014: 404680.
47. [47] Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635: 1-8.
48. [48] Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 2011; 1215: 34-9.
49. [49] Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocinnicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008; 62: 598-605.
50. [50] Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 2008; 31: 897-902.
51. [51] Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150: 5326-33.
52. [52] Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77: 1053-63.
53. [53] Sharma S, Misra CS, Arumugam S, et al. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother Res 2011; 25: 67-73.
54. [54] Lee SM, Yang H, Tartar DM, et al. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 2011; 54: 1136-46.
55. [55] Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
56. [56] Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006; 127: 1109-22.
57. [57] Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and-independent pathways. Diabetes 2008; 57: 1814-23.
58. [58] Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes Metab 2004; 6: 120-6.
59. [59] Tauriainen E, Luostarinen M, Martonen E, et al. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J Nutr Metab 2011; 2011: 525094.
60. [60] Naderali EK. Obesity and cardiovascular dysfunction: a role for resveratrol? Obes Res Clin Pract 2009; 3: 1-52.
61. [61] Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49: 1751-60.
62. [62] Maechler P. Mitochondria as the conductor of metabolic signals for insulin exocytosis in pancreatic β-cells. Cell Mol Life Sci 2002; 59: 1803-18.
63. [63] Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol 2006; 552: 176-81.
64. [64] Szkudelski T. The insulin-suppressive effect of resveratrol-an in vitro and in vivo phenomenon. Life Sci 2008; 82: 430-5.
65. [65] Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 2004; 11: 1595-615.
66. [66] Atten MJ, Godoy-Romero E, Attar BM, Milson T, Zopel M, Holian O. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 2005; 23: 111-9.
67. [67] Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ. Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 2003; 1637: 59-69.
68. [68] Chen WP, Chi TC, Chuang LM, Su MJ. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol 2007; 568: 269-77.
69. [69] Xie S, Sinha RA, Singh BK, Li GD, Han W, Yen PM. Resveratrol induces insulin gene expression in mouse pancreatic α-cells. Cell Biosci 2013; 3: 47.
70. [70] Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132: 257-60.
71. [71] Bagul PK, Middela H, Matapally S, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012; 66: 260-8.
72. [72] Ku CR, Lee HJ, Kim SK, Lee EY, Lee MK, Lee EJ. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly(ADP-ribose) polymerase. Endocr J 2012; 59: 103-9.
73. [73] Chang CC, Chang CY, Huang JP, Hung LM. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol 2012; 55: 192-201.
74. [74] Jiang B, Guo L, Li BY, et al. Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione stransferases μ in diabetic rats. J Med Food 2013; 16: 481-6.
75. [75] Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 2010; 224: 423-32.
76. [76] Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M, Somi MH. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys 2012; 31: 431-8.
77. [77] Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 537-46.
78. [78] Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med (Maywood) 2012; 237: 481-90.
79. [79] Rouse M, Younes A, Egan JM. Resveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activity. J Endocrinol 2014; 223: 107-17.
80. [80] Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008; 374: 117-22.
81. [81] Tan Z, Zhou LJ, Mu PW, et al. Caveolin-3 is involved in the protection of resveratrol against high-fat-diet-induced insulin resistance by promoting GLUT4 translocation to the plasma membrane in skeletal muscle of ovariectomized rats. J Nutr Biochem 2012; 23: 1716-24.
82. [82] Do GM, Jung UJ, Park HJ, et al. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMPactivated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 2012; 56: 1282-91.
83. [83] Chen LL, Zhang HH, Zheng J, et al. Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation. Metabolism 2011; 60: 1598-609.
84. [84] Vingtdeux V, Chandakkar P, Zhao H, Davies P, Marambaud P. Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 2011; 17: 1022-30.
85. [85] Kaeberlein M, McDonagh T, Heltweg B, et al. Substratespecific activation of sirtuins by resveratrol. J Biol Chem 2005; 280: 17038-45.
86. [86] Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
87. [87] Agarwal B, Baur JA. Resveratrol and life extension. Ann N Y Acad Sci 2011; 1215: 138-43.
88. [88] Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab 2011; 31: 1003-19.
89. [89] Frojdo S, Durand C, Pirola L. Metabolic effects of resveratrol in mammals--a link between improved insulin action and aging. Curr Aging Sci 2008; 1: 145-51.
90. [90] Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104: 7217-22.
91. [91] Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P. Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E β-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem 2011; 286: 6049-60.
92. [92] Fullerton MD, Steinberg GR. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010; 59: 551-3.
93. [93] Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007; 6: 759-67.
94. [94] Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol 2006; 4: e31.
95. [95] Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008; 8: 333-41.
96. [96] Imai S. Is Sirt1 a miracle bullet for longevity? Aging Cell 2007; 6: 735-7.
97. [97] Um JH, Park SJ, Kang H, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-63.
98. [98] Chen S, Li J, Zhang Z, et al. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can J Physiol Pharmacol 2012; 90: 237-42.
99. [99] Hoeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab 2012; 23: 444-50.
100. [100] Gomez-Zorita S, Fernandez-Quintela A, Lasa A, Aguirre L, Rimando AM, Portillo MP. Pterostilbene, a dimethyl ether derivative of resveratrol, reduces fat accumulation in rats fed an obesogenic diet. J Agric Food Chem 2014; 62: 8371-8.
101. [101] Jeon BT, Jeong EA, Shin HJ, et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012; 61: 1444-54.
102. [102] Yang SJ, Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 2014; 63: 693-701.
103. [103] Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186-95.
104. [104] Andrade JM, Paraiso AF, de Oliveira MV, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 2014; 30: 915-9.
105. [105] Gomez-Zorita S, Fernandez-Quintela A, Lasa A, Hijona E, Bujanda L, Portillo MP. Effects of resveratrol on obesityrelated inflammation markers in adipose tissue of genetically obese rats. Nutrition 2013; 29: 1374-80.
106. [106] Cho SJ, Park HJ, Jung UJ, Kim HJ, Moon BS, Choi MS. The beneficial effects of combined grape pomace and omija fruit extracts on hyperglycemia, adiposity and hepatic steatosis in db/db mice: a comparison with major index compounds. Int J Mol Sci 2014; 15: 17778-89.
107. [107] Sadi G, Bozan D, Yildiz HB. Redox regulation of antioxidant enzymes: post-translational modulation of catalase and glutathione peroxidase activity by resveratrol in diabetic rat liver. Mol Cell Biochem 2014; 393: 111-22.
108. [108] Burgess TA, Robich MP, Chu LM, Bianchi C, Sellke FW. Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 2011; 146: 556-64.
109. [109] Jimenez-Gomez Y, Mattison JA, Pearson KJ, et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab 2013; 18: 533-45.
110. [110] Yang J, Wang N, Li J, Zhang J, Feng P. Effects of resveratrol on NO secretion stimulated by insulin and its dependence on SIRT1 in high glucose cultured endothelial cells. Endocrine 2010; 37: 365-72.
111. [111] Kim YH, Kim YS, Kang SS, Cho GJ, Choi WS. Resveratrol inhibits neuronal apoptosis and elevated Ca2+/calmodulindependent protein kinase II activity in diabetic mouse retina. Diabetes 2010; 59: 1825-35.
112. [112] Beaudoin MS, Perry CG, Arkell AM, et al. Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. J Physiol 2014; 592: 2519-33.
113. [113] Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010; 298: H833-43.
114. [114] Wang B, Yang Q, Sun YY, et al. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J Cell Mol Med 2014; 18: 1599-611.
115. [115] Mattison JA, Wang M, Bernier M, et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab 2014; 20: 183-90.
116. [116] Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 2010; 26: 212-22.
117. [117] Zheng X, Zhu S, Chang S, et al. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-κB signaling. Eur J Pharmacol 2013; pii: S0014-2999(13)00793-0.
118. [118] Taguchi K, Hida M, Matsumoto T, Ikeuchi-Takahashi Y, Onishi H, Kobayashi T. Effect of short-term polyphenol treatment on endothelial dysfunction and thromboxane A2 levels in streptozotocin-induced diabetic mice. Biol Pharm Bull 2014; 37: 1056-61.
119. [119] Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008; 42: 397-404.
120. [120] Zhou W, Gao G. Resveratrol ameliorates diabetes-induced renal damage through regulating the expression of TGF-β1, Collagen IV and Th17/Treg-related Cytokines in Rats. West Indian Med J 2014; 63: 20-25.
121. [121] Elbe H, Vardi N, Esrefoglu M, Ates B, Yologlu S, Taskapan C. Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol 2015; 34: 100-13.
122. [122] Xu F, Wang Y, Cui W, et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway. Int J Endocrinol 2014; 2014: 289327.
123. [123] Thomas J, Garg ML, Smith DW. Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice. J Nutr Biochem 2014; 25: 313-8.
124. [124] Du LL, Xie JZ, Cheng XS, et al. Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age (Dordr) 2014; 36: 613-23.
125. [125] Xu H, Xiong C, He L, et al. Trans-resveratrol attenuates high fatty acid-induced P2X7 receptor expression and IL-6 release in PC12 cells: possible role of P38 MAPK pathway. Inflammation 2015; 38: 327-37.
126. [126] Mohamed HE, El-Swefy SE, Hasan RA, Hasan AA. Neuroprotective effect of resveratrol in diabetic cerebral ischemic-reperfused rats through regulation of inflammatory and apoptotic events. Diabetol Metab Syndr 2014; 6: 88.
127. [127] Pitocco D, Zaccardi F, Di Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 2010; 7: 15-25.
128. [128] Bashmakov YK, Assaad-Khalil SH, Abou Seif M, et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol 2014; 2014: 816307.
129. [129] Khazaei S, Firouzei MS, Afghari P, Khazaei M. Resveratrol may improve osseointegration of dental implants in type 2 diabetes mellitus patients. J Res Med Sci 2014; 19: 81.
130. [130] Klatsky AL, Friedman GD, Armstrong MA, Kipp H. Wine, liquor, beer, and mortality. Am J Epidemiol 2003; 158: 585-95.
131. [131] Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246-52.
132. [132] Goldberg DM, Yan J, Soleas GJ. Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79-87.
133. [133] Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-7.
134. [134] Nunes T, Almeida L, Rocha JF, et al. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 2009; 49: 1477-82.
135. [135] Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495-504.
136. [136] Ortuno J, Covas M-I, Farre M, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010; 120: 1123-30.
137. [137] Urpi-Sarda M, Jauregui O, Lamuela-Raventos RM, et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005; 77: 3149-55.
138. [138] Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008; 46: 564-70.
139. [139] Burkon A, Somoza V. Quantification of free and proteinbound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008; 52: 549-57.
140. [140] Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53(Suppl 1): S7-15.
141. [141] Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-11.
142. [142] Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392-9.
143. [143] Chow HH, Garland LL, Hsu CH, et al. Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 2010; 3: 1168-75.
144. [144] Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006; 52: 1373-80.
145. [145] la Porte C, Voduc N, Zhang G, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49: 449-54.
146. [146] Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
147. [147] Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49: 482-94.
148. [148] Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM. Absorption of trans-resveratrol in rats. Methods Enzymol 2001; 335: 145-54.
149. [149] Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 49: 472-81.
150. [150] Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 935-42.
151. [151] Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 2011; 4: 1419-25.
152. [152] Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008; 25: 2593-600.
153. [153] de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000; 30: 1047-54.
154. [154] De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000; 30: 857-66.
155. [155] Koide K, Osman S, Garner AL, et al. The use of 3,5,4'-Tri-Oacetylresveratrol as a potential pro-drug for resveratrol protects mice from gamma-irradiation-induced death. ACS Med Chem Lett 2011; 2: 270-274.
156. [156] Oskarsson A, Spatafora C, Tringali C, Andersson AO. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs. Prostate 2014; 74: 839-51.
157. [157] Singh G, Pai RS. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release 2014; 194C: 178-188.
158. [158] Wang S, Su R, Nie S, et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J Nutr Biochem 2014; 25: 363-76.
159. [159] Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 2014; 11: 1285-98.
160. [160] Sessa M, Tsao R, Liu R, Ferrari G, Donsi F. Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion. J Agric Food Chem 2011; 59: 12352-60.
161. [161] Guo L, Peng Y, Yao J, Sui L, Gu A, Wang J. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm 2010; 25: 471-7.
162. [162] Wen X, Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 2006; 34: 1786-92.
163. [163] Remsberg CM, Yanez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 2008; 22: 169-79.
164. [164] http://clinicaltrials.gov/.
165. [165] http://www.sirtispharma.com/.
166. [166] Brasnyo P, Molnar GA, Mohas M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-9.
167. [167] Napoli R, Cozzolino D, Guardasole V, et al. Red wine consumption improves insulin resistance but not endothelial function in type 2 diabetic patients. Metabolism 2005; 54: 306-13.